17.1 Quality Assessment & Troubleshooting

The Total Testing Process In Blood Banking

Quality assessment on the SBB exam spans the total testing process, not just running control material. The three phases work the same way they do across the clinical laboratory, but each carries blood-bank-specific risk because an error here can trigger a hemolytic transfusion reaction rather than just a wrong lab value.

1. Preanalytical — positive patient identification at the bedside, a correctly labeled sample (name, unique identifier, date, phlebotomist identification, and often an ABO-band or wristband check), and rejection of any specimen with a labeling discrepancy. Wrong blood in tube (WBIT) — a specimen drawn from the wrong patient but labeled with the intended patient's information — is the single most dangerous preanalytical error in blood banking, because the resulting ABO type will look entirely plausible while belonging to someone else. Facilities mitigate WBIT with electronic positive patient identification at collection and, for patients without a historical type on file, a policy requiring two independently drawn samples (or one sample plus an electronic identification system) before non-group-O red cells are released.
2. Analytical — reagent and method QC, including daily and per-lot QC on ABO/Rh antisera and reagent red cells, antihuman globulin (AHG) reagent verification with check cells, and comparison of the current result against the patient's historical blood type before release.
3. Postanalytical — correct interpretation and reporting of results into the blood bank information system, tag verification at issue, and documentation that supports traceback if a reaction is reported later.

Reagent QC And The Role Of Check Cells

Every day of use, and with each new reagent lot or shipment, ABO/Rh antisera are tested against known positive and known negative reagent red cells before being used on patient specimens. A reagent that fails to react with its known positive, or reacts with its known negative, is unacceptable and must be pulled from service immediately.

Check cells (Coombs control cells) are the blood bank's equivalent of a statistical QC rule: IgG-sensitized red cells added to every negative antihuman globulin (AHG) test — antibody screen, crossmatch, or direct antiglobulin test. If the AHG reagent and the washing step both worked correctly, adding check cells to a truly negative tube must produce a positive reaction (agglutination). A negative reaction after adding check cells invalidates the test and forces a repeat, because it means either the AHG reagent lost potency or unbound globulins were not adequately washed away and neutralized the reagent — either failure could have masked a true antibody. Reporting a negative crossmatch without a valid check-cell reaction is a common exam trap: the result cannot be trusted until the check cells are shown to work.

Recognizing And Resolving ABO Discrepancies

An ABO discrepancy exists when the forward (cell) type and reverse (serum) type do not agree, and the exam expects you to sort discrepancies into the classic four groups and identify the most likely cause.

Worked example: a specimen forward-types as group O (no reaction with anti-A or anti-B), but the reverse type shows unexpected agglutination with both A1 and B reverse cells, and the plasma is visibly rouleaux-forming in the tube. Saline replacement disperses the rouleaux, and the reverse type resolves to true group O. This is a Group III discrepancy caused by elevated globulins, not a true antibody — skipping the saline replacement step and reporting a Group IV antibody discrepancy instead is exactly the kind of shortcut this exam penalizes.

Investigation of any discrepancy always includes checking the patient's historical ABO/Rh type in the laboratory information system. A current type that disagrees with history — after clerical error is ruled out — must be treated as a possible WBIT event or a genuine physiologic change (recent marrow/stem cell transplant, massive transfusion with group O red cells) and resolved before any non-group-specific unit is released.

Proficiency Testing, Competency, And Accreditation

Proficiency testing (PT) is the primary tool for monitoring accuracy over time, distinct from day-to-day internal QC. CLIA requires enrollment in an approved PT program for regulated analytes, including ABO/Rh grouping, antibody detection, and compatibility testing; blood banks typically enroll through the College of American Pathologists (CAP) or the AABB Proficiency Testing Service. Unsatisfactory PT performance — commonly defined as an unacceptable score on 2 of the last 3 testing events for a regulated analyte — can suspend a laboratory's authority to test that analyte and triggers a mandatory root-cause investigation.

Competency assessment for blood bank testing personnel follows the same CLIA-based six elements used across the clinical laboratory, evaluated at six months and then annually thereafter:

1. Direct observation of routine testing.
2. Monitoring the recording and reporting of results.
3. Review of QC records, PT results, and preventive maintenance records.
4. Direct observation of instrument maintenance and function checks.
5. Assessment of problem-solving skills.
6. Testing of previously analyzed (blind) specimens.

Accreditation and regulatory oversight in blood banking is layered, and the exam expects you to know which body does what:

When an error, adverse reaction, or QC failure is identified, blood banks perform a root cause analysis (RCA) and document a corrective and preventive action (CAPA) plan. A deviation involving a distributed blood product that may have caused a fatality, a serious injury, or that violates federal requirements must also be reported to the FDA as a biological product deviation report (BPDR). A frequently tested nuance: BPDR reporting applies even when no adverse outcome occurred, as long as the deviation could have affected the safety, purity, or potency of the distributed product — waiting for a confirmed patient reaction before reporting is incorrect.